Tissue Regenix gains Medicare and Medicaid Q code

RNS Number : 1625W

Tissue Regenix Group PLC

05 November 2014

 



Tissue Regenix is assigned a Q code by Centers for Medicare and Medicaid Services - allowing wound care centre reimbursement for its DermaPure® dermal allograft

Q code assignment marks a significant step in the on-going commercialisation of DermaPure™, expanding the market for the treatment beyond acute care hospitals to health clinics, physicians and outpatient facilities

YORK, 5 November, 2014 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, today announces its DermaPure™ dermal allograft, has been assigned a Level II Healthcare Common Procedure Coding System (HCPCS) product reimbursement Q code (Q4152) by the Centers for Medicare and Medicaid Services ("CMS"), the US Federal Government funded health programmes.

The new, unique Q code assignment for Tissue Regenix is reflected in the Hospital Outpatient Prospective Payment System Final Rule for CY 2015, released by CMS on October 31, 2014. The new reimbursement code takes effect on January 1, 2015.   

Key Facts

·     Phase II of sales strategy targeting outpatient facilities (wound care clinics, outpatient surgery centres, ambulatory surgery centres and physician's offices where a majority of wounds are treated.)

·     The Q Code will enable these facilities to utilize DermaPure™ for Medicare and Medicaid beneficiaries and receive reimbursement for this product.  This decision will allow greater access to DermaPure™ for clinicians and provide an advanced treatment option for patients suffering from chronic and acute wounds.

Antony Odell, CEO of Tissue Regenix commented: "We are delighted to receive the Q code assignment for DermaPure™ this is an important milestone which allows us to obtain comprehensive reimbursement coverage for DermaPure™ in outpatient facilities, a key channel where skin substitutes are commonly utilized for wound care. 

"The Q code assignment by Centers for Medicaid and Medicare allows Tissue Regenix to target the sizeable US wound and tissue market. Clinicians who have used DermaPure™ have reported positively on its benefits to their patients.  The Q code will significantly expand the number of clinicians that will be able to utilize DermaPure™."

- Ends -

For further information, please contact:

Tissue Regenix Group plc:                                                                  [phone]

Antony Odell

Ian Jefferson

Jefferies International Ltd.                                                                [phone]

Simon Hardy

Harry Nicholas

Newgate Communications                                                                [phone]

Deborah Saw

Andrew Adie                                                                                                                        

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

About DermaPure™

Tissue Regenix's DermaPure® works by taking human donor skin and removing the DNA and cells, using the patented dCELL® process, to leave a natural biological receptive scaffold that can be placed in the wound to aid healing by attracting the patient's own cells to the wound area.

A trial in the UK by NHS Blood and Transplant ('NHSBT') with the University Hospital of South Manchester has shown that patients who have had chronic wounds for an average of 4½ years and who were treated with a single application of Tissue Regenix's DermaPure® have seen an 87% reduction in the size of all wounds, while 60% of patients were completely healed, with virtually no recurrences.

Notes to Editors

Tissue Regenix's Q code assignment relates to the Level II HCPCS coding system, and is used to identify products, supplies and services employed outside of a physician's office, which are not included in the Level I HCPCS coding system.

 

END

 

 

MSCEAAFLELELFAF